Elutia Q1 net loss widens on non-cash warrant revaluation loss

Elutia

14/05/2026 21:21

Overview

US drug-eluting biomatrix developer's Q1 revenue rose 6% year-over-year

Net loss widened, mainly due to non-cash warrant revaluation loss

Gross margin improved to 57.9%, supported by new automated manufacturing process

Outlook

Elutia expects FDA clearance for NXT-41 in Q4 2026 and NXT-41x in H1 2027

Company expects automated manufacturing to support gross margin above 80% at scale

Result Drivers

CARDIOVASCULAR SALES - Growth in Cardiovascular product sales offset decline in SimpliDerm sales

MANUFACTURING AUTOMATION - New automated manufacturing process supported higher gross margin

COMMERCIAL PREPARATIONS - Surgeon engagement and market research underway to validate unmet need and inform launch priorities

Company press release: ID:nGNXb9pXcp

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$3.11 mln
$3 mln (1 Analyst)
Q1 EPS
-$0.17
Q1 Net Income
-$7.47 mln
Q1 Gross Profit
$1.80 mln
Q1 Operating Expenses
$8.15 mln


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Elutia Inc is $5.00, about 376.2% above its May 13 closing price of $1.05

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)